Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D7UD
|
|||
| Former ID |
DIB002523
|
|||
| Drug Name |
AS-013
|
|||
| Synonyms |
Circulase; Ecraprost; Prostaglandin E1 (liposomal), Mitsubishi Pharma/Asahi Glass
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Thrombosis [ICD-11: DB61-GB90; ICD-10: I80-I82] | Phase 3 | [1] | |
| Company |
Taisho Pharmaceutical Co Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C28H48O6
|
|||
| Canonical SMILES |
CCCCCC(C=CC1C(CC(=C1CCCCCCC(=O)OCCCC)OC(=O)CCC)O)O
|
|||
| InChI |
1S/C28H48O6/c1-4-7-11-15-22(29)18-19-23-24(26(21-25(23)30)34-28(32)14-6-3)16-12-9-10-13-17-27(31)33-20-8-5-2/h18-19,22-23,25,29-30H,4-17,20-21H2,1-3H3/b19-18+/t22-,23+,25+/m0/s1
|
|||
| InChIKey |
HITYEEHTEOQBAC-OSIGYOHNSA-N
|
|||
| CAS Number |
CAS 136892-64-3
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Prostaglandin E2 receptor EP1 (PTGER1) | Target Info | Agonist | [1] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Pathways in cancer | ||||
| Panther Pathway | PI3 kinase pathway | |||
| Reactome | Prostanoid ligand receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Prostaglandin Synthesis and Regulation | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Small Ligand GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Effect of lipo-pro-prostaglandin E1, AS-013 on rat inner ear microcirculatory thrombosis. Prostaglandins Leukot Essent Fatty Acids. 1998 Sep;59(3):203-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.